10x Genomics, Inc. Class A Common Stock

Day range

$70.81 – $74.45

Open

$70.81

Prev close

$71.55

Volume

695.17K

Market cap

$9.32B

Shares out

120.21M

P/E

—

P/S

15.11

P/B

11.29

P/FCF

76.77

ROE

-9.1%

ROA

-7.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Preliminary resultsJan 12, 2026

  On January 11, 2026, 10x Genomics, Inc. issued a press release announcing preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025.

• Executive officer appointmentNov 14, 2025

  Dr. Randy Wu, who currently serves as the Company's Vice President, Intellectual Property and Litigation, has been appointed to succeed Mr. Whitaker as General Counsel and Secretary of the Company effective January 1, 2026. Dr. Wu joined the Company in August 2016 after working as an attorney at Orrick, Herrington & Sutcliffe LLP. Dr. Wu holds a Ph.D. in Biophysics from the University of California, San Francisco, a J.D. from Stanford Law School and an A.B. in Chemistry from Harvard University.

• Settlement agreementMay 14, 2025

  On May 12, 2025, 10x Genomics, Inc. (the "Company") entered into a settlement agreement and license agreements (the "Agreements") with Bruker Corporation ("Bruker") resolving all outstanding litigation and other proceedings between the parties across all jurisdictions around the world.

• Workforce reductionMay 8, 2025

  On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company's global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5 million and $6.5 million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025.

• Preliminary resultsJan 13, 2025

  On January 12, 2025, 10x Genomics, Inc. issued a press release announcing preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2024.

• PACBPacific Biosciences of California, Inc.+6.63%
• TWSTTwist Bioscience Corporation Common Stock+3.23%

Days to cover

4.5

Short interest

15.37M

Avg volume

3.39M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth
  positiveGlobeNewswire Inc.· Oct 20, 2026
• 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
  positiveZacks Investment Research· Oct 8, 2026
• Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation
  positiveGlobeNewswire Inc.· Oct 6, 2026
• 10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
  positiveZacks Investment Research· Sep 30, 2026
• Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?
  negativeZacks Investment Research· Sep 9, 2026